All In Biotech

Drug Trial Radar · NCT05991349

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Mar 12, 2024

Primary completion

Nov 30, 2024

Study completion May 31, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2 multicenter, first-in-human study of IBI129. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI129, plan to enroll 22\~180 subjects, and a phase 2 to explore efficacy, safety and tolerability of IBI129 at RP2D in specified types of solid tumor. Approximately 182 evaluable subjects will be enrolled for phase 2

Conditions

  • Solid Tumor

Interventions

  • IBI129Drug

    Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse eventsTime frame: 24 months
  2. Number of subjects with clinically significant changes in physical examination resultsTime frame: 24 months
  3. Number of subjects with clinically significant changes in vital signsTime frame: 24 months
  4. MTD or RP2D of IBI129Time frame: 12 months

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • St George private Hospital

    Kogarah, New South Wales, Australia

  • Wollongong Hospital

    Wollongong, New South Wales, Australia

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Tianjin Medical university cancer institute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.